Microbot Medical (NASDAQ:MBOT) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Profitability

This table compares Microbot Medical and Agenus’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Microbot Medical N/A -77.99% -73.30%
Agenus N/A N/A -103.43%

Volatility & Risk

Microbot Medical has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500.

Institutional and Insider Ownership

4.1% of Microbot Medical shares are owned by institutional investors. Comparatively, 31.7% of Agenus shares are owned by institutional investors. 20.3% of Microbot Medical shares are owned by insiders. Comparatively, 6.4% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Microbot Medical and Agenus, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Microbot Medical 0 1 0 0 2.00
Agenus 0 0 0 0 N/A

Microbot Medical presently has a consensus target price of $1.75, suggesting a potential downside of 80.35%. Given Microbot Medical’s higher probable upside, equities research analysts plainly believe Microbot Medical is more favorable than Agenus.

Earnings and Valuation

This table compares Microbot Medical and Agenus’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Microbot Medical N/A N/A -$7.58 million N/A N/A
Agenus $42.88 million 9.01 -$120.69 million ($1.23) -2.62

Microbot Medical has higher earnings, but lower revenue than Agenus.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob and TipCAT micro-robotic technologies, is developing two product candidates, including the Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; and a self-propelling, semi-disposable endoscope, which is used in colonoscopy procedures. It also holds an intellectual property portfolio that comprises 9 patent families, which include 9 patents granted in the United States, 12 patents granted outside the United States, and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.

About Agenus

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.